ASP Isotopes targets first commercial shipments in 2026 and >$300M EBITDA by 2031

ASP Isotopes Inc.

First commercial shipments of Silicon-28, Carbon-14, and Ytterbium-176 expected in Q2–Q3 2026.
Helium Phase 1 nameplate capacity of 58 MCF/day liquid helium expected by Q3 2026.
Cash, equivalents, and marketable securities totaled $333M as of Dec 31, 2025.
Acquired two U.S. radiopharmacies (Florida Oct 2025, South Carolina) for radiopharmaceutical expansion.
QLE submitted draft S-1 for public listing and signed MOU with large U.S. energy company for enriched uranium.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.